Cargando…

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children

Preterm infants ≤ 35 weeks' gestational age (GA), and children ≤ 24 months of age with bronchopulmonary dysplasia (BPD) or hemodynamically significant congenital heart disease (hsCHD) are at high risk for developing severe respiratory syncytial virus (RSV) disease. In 3 previous randomized, pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambrose, Christopher S, Chen, Xin, Kumar, Veena R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443059/ https://www.ncbi.nlm.nih.gov/pubmed/25483483 http://dx.doi.org/10.4161/hv.32082

Ejemplares similares

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
por: Homaira, Nusrat, et al.
Publicado: (2014)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
por: Forbes, Michael L, et al.
Publicado: (2014)

Is it RSV?
por: Ambrose, Christopher S.
Publicado: (2018)

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo
por: Jacobino, Shamir R., et al.
Publicado: (2018)

Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
por: Stewart, Dan L, et al.
Publicado: (2013)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
por: Ambrose, Christopher S.
Publicado: (2017)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
por: Mulot, Gwenaelle, et al.
Publicado: (2022)

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration
por: Packnett, Elizabeth R., et al.
Publicado: (2023)

A multi‐season national estimate of adult influenza vaccination by US office‐based pediatricians, 2006–2011
por: Toback, Seth. L., et al.
Publicado: (2011)

737. The Prevalence of Diagnosed Chronic Lung Disease in US Infants by Gestational Age: Implications for RSV Policy
por: Ambrose, Christopher S, et al.
Publicado: (2018)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019)

National estimates of poisoning events related to liquid nicotine in young children treated in US hospital emergency departments, 2013–2017
por: Chang, Joanne T., et al.
Publicado: (2019)

Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status
por: Matias, Gonçalo, et al.
Publicado: (2017)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
por: Fernández, Pilar, et al.
Publicado: (2010)

2639. Role of Antimicrobial Stewardship Program (ASP) in Monitoring Community Transmission of Respiratory Syncytial Virus (RSV) to Determine Optimal Timing of Inpatient Palivizumab Administration at a Pediatric Hospital
por: Shapiro, Craig, et al.
Publicado: (2023)

Prediction of serious RSV‐related outcomes in older adults with outpatient RSV respiratory illness during 12 consecutive seasons
por: Kieke, Burney A., et al.
Publicado: (2020)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Compliance with RSV prophylaxis: Global physicians’ perspectives
por: Anderson, Kari S, et al.
Publicado: (2009)

Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines
por: Choi, Yoonyoung, et al.
Publicado: (2021)

Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis
por: Anderson, Evan J., et al.
Publicado: (2017)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study: Palivizumab prophylaxis in children with congenital heart disease
por: Ratti, Chiara, et al.
Publicado: (2023)

Effects of Adjusting for Instrumental Variables on the Bias and Precision of Propensity Score Weighted Estimators: Analysis Under Complete, Near, and No Positivity Violations
por: Choi, Byeong Yeob, et al.
Publicado: (2023)

Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
por: Mejías, Asunción, et al.
Publicado: (2007)

Development of a palivizumab specialty pharmacy management program
por: Harlan, Lana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i26n140meqr66r5fsck0aq5cdp